Erschienen in:
09.09.2019 | Translational Research and Biomarkers
Editorial: A Novel Monoclonal Antibody-Targeting Angiogenesis by Inhibiting Secreted Frizzled-Related Protein 2
verfasst von:
Julie E. Lang, MD, FACS, William W. Tseng, MD, Irene Kang, MD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 13/2019
Einloggen, um Zugang zu erhalten
Excerpt
The legendary surgeon-scientist Judah Folkman contributed a wealth of discoveries on the fundamental role of angiogenesis in cancer and other diseases.
1 This line of investigation led to more than 50 angiogenesis inhibitors being investigated in clinical trials and at least 10 that are currently approved by the US FDA.
2 Angiogenesis inhibitors work via a variety of mechanisms of action. Some specifically bind to (1) vascular endothelial growth factor (VEGF) or its receptor; (2) other growth factors such as platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), and epidermal growth factor (EGF); or (3) receptors or proteins on endothelial cells, blocking the growth of blood vessels.
3,
4 Angiogenesis inhibitors remain an attractive topic for preclinical development for cancer therapy. …